Connect with us
DAPA Banner
DAPA Coin
DAPA
COIN PAYMENT ASSET
PRIVACY · BLOCKDAG · HOMOMORPHIC ENCRYPTION · RUST
ElGamal Encrypted MINE DAPA
🚫 GENESIS SOLD OUT
DAPAPAY COMING

Business

US announces new tariffs over forced labour concerns

Published

on

US announces new tariffs over forced labour concerns

It comes after the US Supreme Court struck down many of US President Donald Trump’s previous duties in February.

Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

Nation's largest carbon farming project unveiled on WA's south coast

Published

on

Nation's largest carbon farming project unveiled on WA's south coast

Some 16 million trees will be planted across 28,000ha of Great Southern farmland for a project worth an estimated $40 million.

Continue Reading

Business

Paladin Energy Shares Surge 11% on Strong Uranium Market Momentum and Operational Gains

Published

on

Fluence Energy Stock Explodes 40% on Record $5.6B Backlog and

Paladin Energy Ltd shares jumped more than 11% on Wednesday, closing at $11.85 after gaining $1.22, as investors bet on continued strength in the global uranium sector amid rising nuclear energy demand and the company’s solid production ramp-up at its flagship Langer Heinrich mine in Namibia.

The Australian-listed uranium producer, also traded on the TSX under PDN, saw heavy trading volume as broader sector optimism lifted several peers. Paladin’s market capitalization climbed toward $4.8 billion following the sharp daily move, reflecting renewed confidence in its growth trajectory as a significant independent uranium supplier.

The surge comes amid a favorable backdrop for uranium companies. Global interest in nuclear power as a reliable, low-carbon energy source has intensified, driven by data center electricity needs for artificial intelligence, energy security concerns in Europe, and policy support in multiple nations. Spot uranium prices have remained elevated throughout 2026, supporting producer margins.

Paladin’s primary asset, the 75%-owned Langer Heinrich Mine in Namibia, has been a key driver of recent performance. The company has successfully ramped up production at the restarted operation, achieving consistent output improvements and cost efficiencies. Recent quarterly reports highlighted sequential gains in uranium production and sales, with the mine approaching target capacity levels.

Advertisement

In its March 2026 quarter update, Paladin revised full-year production guidance upward by 11%, signaling confidence in operational delivery. The company reported strong sales revenue and maintained disciplined cost control despite industry-wide inflationary pressures on mining inputs.

Chief Executive Officer Ian Purdy has emphasized the strategic positioning of Langer Heinrich in a tightening uranium market. The mine’s large-scale, low-cost profile positions Paladin to benefit from long-term contracts with utility customers across the United States, Europe and Asia.

Analysts largely maintain positive outlooks on the stock. Consensus price targets hover around A$13.00-A$13.20, implying additional upside from current levels, with some forecasts reaching as high as A$17. Several brokers cite the company’s robust balance sheet, exploration portfolio in Canada and Australia, and exposure to structural supply deficits as key attractions.

Paladin also holds development assets such as the Patterson Lake South project in Canada’s Athabasca Basin, one of the world’s premier uranium districts. Progress on regulatory approvals and feasibility work at these sites adds longer-term growth potential beyond current production.

Advertisement

The company’s financial turnaround has been notable. For the nine months ending March 31, 2026, Paladin swung to a modest net profit from prior losses, supported by higher realized prices and volumes. While some cash flow metrics drew scrutiny, overall liquidity remains solid with substantial working capital.

Uranium market fundamentals underpin the optimism. Supply constraints persist due to years of underinvestment following the Fukushima disaster, while demand forecasts continue rising. Utilities are securing long-term supply agreements, often at premium prices, to ensure fuel security for reactor fleets.

Namibia, home to Langer Heinrich, has emerged as a stable and attractive jurisdiction for uranium mining. The country offers established infrastructure and government support for resource development, helping Paladin accelerate its ramp-up schedule.

Investors appear to be rewarding Paladin’s execution after earlier volatility. The stock has delivered strong multi-year gains, though it experienced pullbacks during periods of sector-wide corrections. Wednesday’s 11.48% advance recouped some recent ground and pushed the shares closer to 52-week highs seen earlier in 2026.

Advertisement

Broader sector dynamics also played a role. Several other uranium developers and producers posted gains amid positive sentiment around nuclear energy’s role in global decarbonization. Paladin’s relatively pure-play exposure makes it a favored vehicle for investors seeking leveraged upside to uranium prices.

Risks remain, however. Uranium prices can be volatile, and any slowdown in reactor restarts or new builds could pressure the market. Operational challenges at Langer Heinrich, such as processing plant reliability or labor issues, could affect guidance. Geopolitical factors in Africa and regulatory hurdles in Canada represent additional considerations.

Paladin has worked to mitigate these through diversified project pipelines and conservative financial management. The company completed equity raisings in prior periods to strengthen its balance sheet, providing flexibility for development and potential acquisitions.

Looking forward, analysts expect Paladin to generate increasing free cash flow as Langer Heinrich reaches steady-state production. This could enable dividend considerations or accelerated investment in its exploration portfolio. The company continues to engage with substantial holders and institutional investors, as evidenced by recent shareholding disclosures.

Advertisement

For retail and institutional investors alike, Paladin represents a compelling way to gain exposure to the nuclear renaissance. Its scale as a producing entity distinguishes it from pure explorers, while growth projects provide upside optionality.

Market watchers will closely monitor upcoming quarterly production reports and any updates on Canadian asset advancements. With the Northern Hemisphere summer traditionally a quieter period for uranium news, any positive surprises could sustain momentum.

Paladin’s dual listing on the ASX and TSX broadens its investor base, particularly appealing to North American funds interested in critical minerals and clean energy plays. Trading liquidity has improved as the company’s profile rises alongside the uranium sector.

As global energy policies evolve, Paladin’s ability to deliver reliable uranium supply positions it favorably. Wednesday’s sharp share price reaction underscores the market’s appetite for high-quality operators in this space, especially those demonstrating both current production and future growth potential.

Advertisement

The uranium story remains intact despite periodic volatility, with many experts forecasting multi-year strength. For Paladin Energy, sustained operational success at Langer Heinrich could translate into further shareholder value as the company solidifies its role in the global nuclear fuel supply chain.

Continue Reading

Business

Eternal to ICICI Bank: 15 stocks on Axis Securities buy list for June – Add to cart

Published

on

Eternal to ICICI Bank: 15 stocks on Axis Securities buy list for June - Add to cart

Axis warns that higher crude oil prices, rupee weakness, inflation and a weak monsoon remain important risks. It advises investors to keep 10-15% liquidity available and focus on high-quality companies with strong balance sheets and earnings visibility.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)

Continue Reading

Business

Eli Lilly to use GLP-1 windfall to fund M&A and diversify pipeline

Published

on

Eli Lilly to use GLP-1 windfall to fund M&A and diversify pipeline
Lilly’s Van Naarden: Nothing is off the table for dealmaking

Jacob Van Naarden is busy. 

In addition to running Eli Lilly‘s oncology business, he’s now responsible for finding the drugmaker’s next opportunities as head of business development. And Lilly, now the world’s largest pharmaceutical company, is hungrier than ever for deals. 

“The company’s financial strength right now, driven mostly by the weight loss business, is so strong,” Van Naarden said in an interview at the American Society of Clinical Oncology’s annual meeting. “We have this really like almost generational opportunity to redeploy that capital in all of our disease areas to not only fuel growth for the company in the decades to come, but to help a lot more patients with all different kinds of diseases, and so we’re executing against that strategy.”

Jacob S. Van Naarden,
Executive Vice President; President of Lilly Oncology and Head of Corporate Business Development, Eli Lilly and Company.

Advertisement

Courtesy: Eli Lilly

Not even halfway into the year, Lilly has already announced it will spend more than $10 billion upfront and potentially up to $25 billion on eight acquisitions. For all of last year, Lilly spent about $4 billion on roughly 40 deals. 

The spending spree reflects an intentional shift in how Lilly approaches dealmaking now that the company is larger and more highly valued than ever before. The company’s market capitalization now stands at about $1 trillion, up from $190 billion in 2021, according to data from LSEG. Lilly is the first health-care company to join the trillion-dollar club, which is dominated by tech firms.

Previously, the drugmaker primarily liked to place bets on early-stage assets that were inexpensive because they were riskier. Now, it’s using the windfall from its GLP-1 drugs like Mounjaro and Zepbound to pursue experimental drugs that are more likely to work – and carry larger price tags because of it. 

Advertisement

“These things are medicines,” Van Naarden said in a separate interview at his Stamford, Connecticut office. “How big will they be? What’s the development plan? When will they get approved? Like, I don’t yet know all that. Obviously we have projections, but you can see enough to say OK, this is real, and we can underwrite paying a bigger price than we pay for some real preclinical thing. So that’s been a big part of where we’ve been focused in addition to running the high-volume, early-stage strategy.”

Two Mounjaro KwikPen injection pens are in front of the Eli Lilly logo displayed on a screen in this illustration photo in Athens, Greece, on March 1, 2026.

Nikos Pekiaridis | Nurphoto | Getty Images

Van Naarden said his boss, Lilly CEO Dave Ricks, approached him last fall about leading business development in addition to his main job as head of Lilly’s oncology business. The company wanted to sharpen its dealmaking skills and start widening its aperture beyond the early bets where Lilly liked to focus. 

Advertisement

He started to execute the strategy early this year.

Lilly’s planned acquisition of Centessa Pharmaceuticals, announced in March, could reach up to $7.8 billion if the company meets certain milestones for its experimental drugs for sleep disorders like narcolepsy. That would make it Lilly’s second-ever largest deal behind the company’s $8 billion acquisition of Loxo Oncology in 2019. Van Naarden was the chief operating officer at Loxo at the time.

While large for Lilly, deals of roughly $8 billion are still small compared to agreements from other large pharmaceutical companies. It raises the question of how big Lilly could go.

Van Naarden doesn’t want to set arbitrary size spending limits. He says it’s about how compelling the science is and how big the opportunity is for patients and for Lilly.

Advertisement

Some of the deals announced this year fall under Lilly’s current specialties of oncology, neuroscience, cardiometabolic health and immunology. Others, like Lilly’s recently announced acquisitions of three vaccine companies, will take the company into new areas. 

“We’re looking at all kinds of things that don’t neatly fit into one of those four buckets, so don’t be surprised if we have more to come for things that you know don’t perhaps neatly fit within what we’ve done historically,” Van Naarden said this week at ASCO. “If you see it, it means we’re excited, and we think we can make a big impact.”

Is there anything that’s off the table?

“No,” he said, “not really.”

Advertisement
Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.
Continue Reading

Business

Dudley’s Aluminium lands Cardiff and Vale new campuses contract

Published

on

Business Live

It will partner with main contractor Bouygues UK

An artist's impression of what the new Cardiff and Vale College campus on land south of Hood Road, Barry could look like

Artist impression of Cardiff and Vale College;s Barry waterfront campus.(Image: Sheppard Robson)

Fabricator Dudley’s Aluminium is supporting the construction of two campuses for Cardiff and Vale College in the Vale of Glamorgan.

Dudley’s will be partnering with main contractor Bouygues UK on the under construction campuses for the largest college provider in the UK and the biggest in Wales.

Advertisement

The college, in a £119m investment , is delivering a new Barry waterfront campus, a community-focused college in the heart of the town, which will replace its existing ageing Colcot Road campus.

Its Advanced Technology Centre near Cardiff Airport will meet the skills needs of employers, apprentices and those working in advanced technologies. Both campuses are scheduled to open in September 2027.

Cardiff-based Dudley’s and will install metal technology curtain walling, windows and high insulation doors on the builds.

Artist impression of the Advanced Technology Centre.

Steve Muir, commercial director at Dudley’s Aluminium, said: “We are thrilled to be working with Bouygues on Cardiff and Vale College’s new campuses in the Vale of Glamorgan. Our proven track record in the education sector will ensure the project is delivered to high standards, providing quality teaching and learning environments that meet the needs of students, employers and the wider community.”

Advertisement

Since 1993, Dudley’s Aluminium has provided full in-house design, fabrication and installation capabilities, completing projects across the education, health, commercial, retail, residential and defence sectors throughout the UK and Channel Islands.

Continue Reading

Business

BioPharma Credit provides up to $150m loan to Mineralys

Published

on


BioPharma Credit provides up to $150m loan to Mineralys

Continue Reading

Business

Buy or Sell Palantir Stock in 2026? Analysts Weigh AI Momentum Against High Valuation

Published

on

Palantir

NEW YORK — Palantir Technologies Inc. shares have delivered substantial gains in recent years but now trade at elevated valuations as the data analytics company capitalizes on surging demand for artificial intelligence platforms across government and commercial sectors in 2026.

As of early June, Palantir stock closed around $152 after recent volatility, reflecting both strong fundamental performance and investor concerns over premium multiples. Wall Street maintains a moderate buy consensus, with average 12-month price targets near $193, implying roughly 27% upside from current levels.

The company reported exceptional first-quarter results in May, with revenue reaching $1.633 billion, an 85% increase year-over-year. U.S. revenue grew 104%, driven by 133% growth in commercial sales and 84% expansion in government contracts. Palantir raised its full-year 2026 revenue guidance to $7.65-$7.66 billion, signaling 71% growth.

CEO Alex Karp highlighted the accelerating U.S. market as central to the company’s trajectory. “Momentum surged as we grew 85% last quarter — our highest-ever year-over-year growth rate — by more than doubling our U.S. business,” he stated in the earnings release.

Advertisement

Palantir’s Artificial Intelligence Platform (AIP) has become a key growth driver, enabling organizations to deploy AI rapidly while maintaining data governance. Strong adoption in both defense and enterprise segments has fueled optimism, with major contracts including a $300 million deal with the U.S. Department of Agriculture.

Analysts largely favor the stock. Of 31 covering firms, 19 rate it buy, 10 hold and two sell. Consensus targets range from a low of $90 to a high of $255, with many citing continued commercial momentum and government tailwinds.

Supporters point to Palantir’s sticky customer relationships and expanding addressable market. The company’s focus on large deals exceeding $1 million has yielded consistent total contract value growth. Its platforms serve critical national security needs while expanding into commercial applications like supply chain optimization and financial services.

However, valuation remains a central debate. Palantir trades at forward price-to-earnings multiples exceeding 150 times, far above traditional software peers. Critics argue that any slowdown in AI spending or execution challenges could trigger significant multiple compression.

Advertisement

Recent pullbacks, including a drop from 2025 highs near $207, have created entry points for some investors. Rosenblatt analysts described the dip as a buying opportunity, citing robust earnings momentum and defense-AI synergies.

Risks include heavy dependence on government contracts, which can face budgetary and political uncertainties. Insider selling by executives, including CEO Alex Karp, has also drawn attention, though such activity is common in growth companies with substantial equity compensation.

On the positive side, Palantir’s Rule of 40 score — combining revenue growth and profitability — reached 145% in the first quarter, demonstrating exceptional balance between expansion and margins. Adjusted operating margins hit 60%, with strong free cash flow generation.

Commercial growth represents the biggest upside catalyst. U.S. commercial revenue guidance was raised sharply, reflecting accelerating enterprise adoption of AI tools. Analysts expect this segment to become an even larger contributor as more Fortune 500 companies integrate Palantir’s platforms.

Advertisement

The company’s dual focus on government stability and commercial upside differentiates it from pure-play AI hardware firms. While competitors face cyclical semiconductor demand, Palantir benefits from recurring software revenue and platform lock-in effects.

Broader market context influences the outlook. Strong AI enthusiasm has supported technology stocks, but higher interest rates and potential economic slowdowns could pressure high-valuation names. Palantir’s beta makes it sensitive to shifts in risk sentiment.

Longer-term forecasts remain constructive. Some analysts project Palantir could reach $225 per share by early 2027 if earnings growth continues beating expectations. The company has consistently exceeded consensus estimates, often by double-digit margins.

For buy-and-hold investors, the case rests on Palantir establishing itself as essential AI infrastructure. Its ontology-based approach to data integration offers advantages in complex environments where competitors struggle.

Advertisement

Skeptics highlight execution risks and competition from larger cloud providers and specialized AI firms. Sustaining triple-digit commercial growth will require flawless delivery and continued innovation.

Portfolio allocation matters. Growth-oriented investors with high risk tolerance may add to positions on dips, while conservative accounts might limit exposure or wait for better valuation entry points.

Recent trading patterns show heightened volatility. Shares surged on strong earnings but faced profit-taking as some questioned sustainability at current levels. Volume remains robust, indicating sustained investor interest.

Palantir’s balance sheet strength provides flexibility for acquisitions or share repurchases, though the company has prioritized growth investments. Its cash position and minimal debt offer resilience during uncertain periods.

Advertisement

As 2026 progresses, key catalysts include quarterly results, new contract announcements and potential expansion in international markets. The second half of the year could clarify whether commercial momentum can offset any government spending fluctuations.

Investment decisions ultimately depend on individual circumstances, time horizons and risk appetite. While consensus leans bullish, the wide dispersion in price targets reflects genuine debate over appropriate valuation for a high-growth AI software leader.

Palantir has transformed from a niche data analytics firm into a prominent AI player. Its 2026 performance will test whether exceptional growth justifies premium pricing or if normalization lies ahead.

Investors should monitor upcoming earnings for sustained U.S. commercial acceleration and margin trends. In a dynamic technology landscape, Palantir’s ability to execute on its ambitious guidance will determine if the stock rewards shareholders over the remainder of 2026 and beyond.

Advertisement
Continue Reading

Business

Opinion: Fracking forecast a split decision

Published

on

Opinion: Fracking forecast a split decision

OPINION: Roger Cook’s gas supply ultimatum will create cracks in Labor unity.

Continue Reading

Business

Suno raises $400 million at $5.4 billion valuation

Published

on


Suno raises $400 million at $5.4 billion valuation

Continue Reading

Business

Market correction nearing its end; bet on banking, pharma: Rohit Srivastava

Published

on

Market correction nearing its end; bet on banking, pharma: Rohit Srivastava
After a sharp correction over the last few trading sessions, investors are grappling with questions about whether the market has further downside ahead or if the current weakness is creating fresh buying opportunities. According to Rohit Srivastava, Founder, Strike Money Analytics & Indiacharts the ongoing correction may be closer to its conclusion than many fear, with select sectors showing encouraging signs of strength.

Nifty Approaching a Key Support Zone

While benchmark indices have witnessed pressure in recent days, Srivastava believes the market is approaching an important technical support area that could potentially mark the end of the current correction phase.

“So, from the bottom that we made in April, which was at 22,182, and then we peaked in April near the end at around 24,601, and we take a 61% retracement of that, we get a level closer to 23,077. So, that, I think, becomes the final major support for this dip that is going on, so that leaves around 80 to 100 points still on the downside. But that also means that the risk may be limited when we think of how much more downside there is. We should, of course, wait before we actually can make some kind of entry point. But what we are looking at is the potential for a possible turn in the market from down to up once we are done with this selling. So, patience, but we are getting to the end of this correction.”

Advertisement

The assessment suggests that while some near-term weakness cannot be ruled out, the broader risk-reward equation may gradually begin shifting in favour of investors willing to wait for confirmation of a market turnaround.

Banking Emerges as a Preferred Bet
Among sectors, banking appears to be one of the strongest candidates for fresh investment ideas during the current market decline. Srivastava highlighted a notable divergence between the benchmark Nifty and Bank Nifty, suggesting relative resilience in financial stocks.
“As a sector, it is something we have been avoiding for most of the year, and I have not exactly been positive on it for a long time. So, IT is not a sector I recommend at any point in time till the worst is very, very certainly over. I do think banking is a good place. In fact, there is an interesting divergence between banking and Nifty, where the Bank Nifty has not broken the lows that it made in May, whereas Nifty has already done so. So, there is some kind of a positive divergence between the two. So, banking comes across as one segment where we would want to very definitely find ideas to buy into in this dip.”The comments indicate that investors looking for relative strength amid market volatility may find banking stocks better positioned than several other sectors.

Energy and Metals Gain Momentum
Apart from financials, Srivastava sees merit in sectors that have been benefiting from improving commodity trends and stronger underlying demand dynamics.

“The other areas that could be of interest could be going back to the energy sector, which was performing pretty well, and also metals. People often may miss out that you are seeing a strong rally in metals, but also metal prices. Like overnight, you have seen gains in copper, zinc, nickel, everything, and that could result in extended gains in the metal sector as well.”

The rise in industrial metal prices globally has strengthened the outlook for metal producers, potentially extending the sector’s recent outperformance.

Advertisement

Autos Still in Consolidation Mode
While the automobile sector remains an important part of the broader market story, Srivastava believes the segment may require more time before a decisive uptrend emerges.

“Well, autos seem to be consolidating. The real big kick for autos will come only when we can actually get a turn in the interest-rate cycle. They may still do well. There have been outperformances in certain segments of the two-wheeler pack, like you saw a very strong rally in between in Tata Motors passenger vehicles, so that kind of thing is happening. But it is still not across the board. So, give it a while for the other stocks to consolidate and pick up. So, we will be a little slower in picking up on the auto side.”

The view suggests that although pockets of strength exist, investors may need to be selective rather than expecting a broad-based rally across the entire auto universe.

Pharma’s Long-Term Breakout Remains Intact
One of the most constructive sectoral outlooks offered by Srivastava was for pharmaceuticals. He pointed to a significant technical breakout in the Nifty Pharma index that could support sustained gains over the medium to long term.

Advertisement

“Yes, the pharma index is on a pretty strong footing if I take a slightly longer-term view. We broke beyond 23,500 on the Nifty Pharma index; that was a breakout of a two-year consolidation. Now, it is only pulling back to take support there, and once it is done, then we should be headed towards possibly 30,000-plus on the pharma index in a one-, one-and-a-half-year kind of time horizon.”

As markets navigate a period of correction and uncertainty, Srivastava’s outlook suggests that the bulk of the downside may already be behind investors. While caution remains warranted in the near term, sectors such as banking, metals, energy, and pharmaceuticals appear better positioned for the next phase of market leadership. At the same time, IT remains a sector to avoid until clearer signs of recovery emerge, while autos may require more patience before delivering broad-based returns.

Continue Reading

Trending

Copyright © 2025